Publications

  1. Luo Y, Gadd ME, Qie Y, Otamendi-Lopez A, Sanchez-Garavito JE, Brooks MM, Ulloa Navas MJ, Hundal T, Li S, Jones VK, Lou Y, Patel T, Dronca R, Kharfan-Dabaja MA, Dong H, Quinones-Hinojosa A, Qin H. Solid cancer-directed CAR T cell therapy that attacks both tumor and immunosuppressive cells via targeting PD-L1. Mol Ther Oncol. 2024 Dec 19; 32 (4):200891 Epub 2024 Oct 05
    View PubMed
  2. Bansal A, Lavoie RR, Lucien F, Kethamreddy M, Wootla B, Dong H, Park SS, Pandey MK. Synthesis and evaluation of anti-PD-L1-B11 antibody fragments for PET imaging of PD-L1 in breast cancer and melanoma tumor models. Sci Rep. 2024 Aug 22; 14 (1):19561
    View PubMed
  3. Sun ND, Carr AR, Krogman EN, Chawla Y, Zhong J, Guttormson MC, Chan M, Hsu MA, Dong H, Bogunovic D, Pandey A, Rogers LM, Ting AT. TBK1 and IKKepsilon protect target cells from IFNgamma-mediated T cell killing via an inflammatory apoptotic mechanism. bioRxiv. 2024 Aug 8 Epub 2024 Aug 08
    View PubMed
  4. Zhang Y, Liu J, Lo TW, Kim Y, Lucien F, Dong H, Liu Y. A digital microfluidic device integrated with electrochemical sensor and 3D matrix for detecting soluble PD-L1. Biosens Bioelectron X. 2024 Aug; 19 Epub 2024 May 17
    View PubMed
  5. Tomlinson JL, Li B, Yang J, Loeuillard E, Stumpf HE, Kuipers H, Watkins R, Carlson DM, Willhite J, O'Brien DR, Graham RP, Chen X, Smoot RL, Dong H, Gores GJ, Ilyas SI. Syngeneic murine models with distinct immune microenvironments represent subsets of human intrahepatic cholangiocarcinoma. J Hepatol. 2024 Jun; 80 (6):892-903 Epub 2024 Mar 07
    View PubMed
  6. Zheng J, Wang L, Zhao S, Zhang W, Chang Y, Bosco DB, Huang T, Dheer A, Gao S, Xu S, Ayasoufi K, Al-Kharboosh R, Qi F, Xie M, Johnson AJ, Dong H, Quinones-Hinojosa A, Wu LJ. TREM2 mediates MHCII-associated CD4+ T-cell response against gliomas. Neuro Oncol. 2024 May 3; 26 (5):811-825
    View PubMed
  7. Hieken TJ, Nelson GD, Flotte TJ, Grewal EP, Chen J, McWilliams RR, Kottschade LA, Yang L, Domingo-Musibay E, Dronca RS, Yan Y, Markovic SN, Dimou A, Montane HN, Erskine CL, Piltin MA, Price DL, Khariwala SS, Hui J, Strand CA, Harrington SM, Suman VJ, Dong H, Block MS. Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable Stage III melanoma: the Phase II NeoACTIVATE trial. Nat Commun. 2024 Feb 16; 15 (1):1430
    View PubMed
  8. Loeuillard EJ, Li B, Stumpf HE, Yang J, Willhite JR, Tomlinson JL, Rohakhtar FR, Simon VA, Graham RP, Smoot RL, Dong H, Ilyas SI. Noncanonical TRAIL Signaling Promotes Myeloid-Derived Suppressor Cell Abundance and Tumor Growth in Cholangiocarcinoma. Cell Mol Gastroenterol Hepatol. 2024; 17 (5):853-876 Epub 2024 Jan 14
    View PubMed
  9. Gicobi JK, Mao Z, DeFranco G, Hirdler JB, Li Y, Vianzon VV, Dellacecca ER, Hsu MA, Barham W, Yan Y, Mansfield AS, Lin Y, Wu X, Hitosugi T, Owen D, Grams MP, Orme JJ, Lucien F, Zeng H, Park SS, Dong H. Salvage therapy expands highly cytotoxic and metabolically fit resilient CD8(+) T cells via ME1 up-regulation. Sci Adv. 2023 Nov 17; 9 (46):eadi2414 Epub 2023 Nov 15
    View PubMed
  10. Zhong W, Lu Y, Han X, Yang J, Qin Z, Zhang W, Yu Z, Wu B, Liu S, Xu W, Zheng C, Schuchter LM, Karakousis GC, Mitchell TC, Amaravadi R, Flowers AJ, Gimotty PA, Xiao M, Mills G, Herlyn M, Dong H, Mitchell MJ, Kim J, Xu X, Guo W. Upregulation of exosome secretion from tumor-associated macrophages plays a key role in the suppression of anti-tumor immunity. Cell Rep. 2023 Oct 31; 42 (10):113224 Epub 2023 Oct 08
    View PubMed
  11. Santasusagna S, Zhu S, Jawalagatti V, Carceles-Cordon M, Ertel A, Garcia-Longarte S, Song WM, Fujiwara N, Li P, Mendizabal I, Petrylak DP, Kelly WK, Reddy EP, Wang L, Schiewer MJ, Lujambio A, Karnes J, Knudsen KE, Cordon-Cardo C, Dong H, Huang H, Carracedo A, Hoshida Y, Rodriguez-Bravo V, Domingo-Domenech J. Master transcription factor reprograming unleashes selective translation promoting castration resistance and immune evasion in lethal prostate cancer. Cancer Discov. 2023 Sep 7 Epub 2023 Sept 07
    View PubMed
  12. Rodrigues Pessoa R, Zhang H, Zganjar A, Nabavizadeh R, Packiam VT, Lohse CM, Cheville JC, Pagliaro LC, Costello BA, Boorjian SA, Thompson RH, Lucien F, Dong H, Leibovich BC. Circulating antigen-primed cytotoxic T-cells in patients with renal tumors treated with surgery. Urol Oncol. 2023 Sep; 41 (9):393.e1-393.e7 Epub 2023 July 04
    View PubMed
  13. Wu Y, Hu SS, Zhang R, Goplen NP, Gao X, Narasimhan H, Shi A, Chen Y, Li Y, Zang C, Dong H, Braciale TJ, Zhu B, Sun J. Single cell RNA sequencing unravels mechanisms underlying senescence-like phenotypes of alveolar macrophages. iScience. 2023 Jul 21; 26 (7):107197 Epub 2023 June 23
    View PubMed
  14. Wu X, Manske MK, Ruan GJ, Witter TL, Nowakowski KE, Abeykoon JP, Tang X, Yu Y, Gwin KA, Wu A, Taupin V, Bhardwaj V, Paludo J, Dasari S, Dong H, Ansell SM, Badley AD, Schellenberg MJ, Witzig TE. Secreted ORF8 induces monocytic pro-inflammatory cytokines through NLRP3 pathways in patients with severe COVID-19. iScience. 2023 Jun 16; 26(6):106929. Epub 2023 May 18.
    View PubMed
  15. An Z, Hsu MA, Gicobi JK, Xu T, Harrington SM, Zhang H, Pavelko KD, Hirdler JB, Lohse CM, Nabavizadeh R, Pessoa RR, Sharma V, Thompson RH, Leibovich BC, Dong H, Lucien F. A Novel PD-L1 Antibody Promotes Antitumor Function of Peripheral Cytotoxic Lymphocytes after Radical Nephrectomy in Patients with Renal Cell Carcinoma. J Immunol. 2023 Jun 15; 210 (12):2029-2037
    View PubMed
  16. Liu X, Aneas I, Sakabe N, Anderson RL, Billstrand C, Paz C, Kaur H, Furner B, Choi S, Prichina AY, Enninga EAL, Dong H, Murtha A, Crawford GE, Kessler JA, Grobman W, Nobrega MA, Rana S, Ober C. Single cell profiling at the maternal-fetal interface reveals a deficiency of PD-L1(+) non-immune cells in human spontaneous preterm labor. Sci Rep. 2023 May 16; 13 (1):7903
    View PubMed
  17. Gicobi JK, Dellacecca ER, Dong H. Resilient T-cell responses in patients with advanced cancers. Int J Hematol. 2023 May; 117 (5):634-639 Epub 2022 July 21
    View PubMed
  18. Tu X, Mutter R, Lou Z, Dong H. A new pd-l1 antibody h1a causes pd-l1 degradation and sensitizes cancer cells for cytotoxic therapy. Journal of Immunology. 2023; 210(1 Suppl):230.06.
  19. Zhu M, Zhang H, Pedersen KS, Foster NR, Jaszewski BL, Liu X, Hirdler JB, An Z, Bekaii-Saab TS, Halfdanarson TR, Boland PM, Yan Y, Hubbard JH, Ma WW, Yoon HH, Revzin A, Fernandez-Zapico ME, Overman MJ, McWilliams RR, Dong H. Understanding Suboptimal Response to Immune Checkpoint Inhibitors. Adv Biol (Weinh). 2023 Apr; 7 (4):e2101319 Epub 2022 Mar 27
    View PubMed
  20. Farooqui N, Zaidi M, Vaughan L, McKee TD, Ahsan E, Pavelko KD, Villasboas JC, Markovic S, Taner T, Leung N, Dong H, Alexander MP, Herrmann SM. Cytokines and Immune Cell Phenotype in Acute Kidney Injury Associated With Immune Checkpoint Inhibitors. Kidney Int Rep. 2023 Mar; 8 (3):628-641 Epub 2022 Dec 05
    View PubMed
  21. Barham W, Hsu M, Liu X, Harrington SM, Hirdler JB, Gicobi JK, Zhu X, Zeng H, Pavelko KD, Yan Y, Mansfield AS, Dong H. A Novel Humanized PD-1/PD-L1 Mouse Model Permits Direct Comparison of Antitumor Immunity Generated by Food and Drug Administration-Approved PD-1 and PD-L1 Inhibitors. Immunohorizons. 2023 Jan 1; 7 (1):125-139
    View PubMed
  22. Lucien F, Kim Y, Qian J, Orme JJ, Zhang H, Arafa A, Abraha F, Thapa I, Tryggestad EJ, Harmsen WS, Kosti J, Ali H, Lowe VJ, Johnson GB, Kwon ED, Dong H, Park SS. Tumor-Derived Extracellular Vesicles Predict Clinical Outcomes in Oligometastatic Prostate Cancer and Suppress Antitumor Immunity. Int J Radiat Oncol Biol Phys. 2022 Nov 15; 114 (4):725-737 Epub 2022 June 04
    View PubMed
  23. Yoon HH, Dong H, Shi Q. Impact of PD-1 Blockade in Nonresponders: Pitfalls and Promise. Clin Cancer Res 2022 Aug 2; 28 (15):3173-3175
    View PubMed
  24. Zhu M, Chen C, Foster NR, Hartley C, Mounajjed T, Salomao MA, Fruth BF, Beamer SE, Kim Y, Harrington SM, Pitot HC, Sanhueza CT, Feng Y, Herrmann J, McWilliams RR, Lucien F, Huang BQ, Ma WW, Bekaii-Saab TS, Dong H, Wigle D, Ahn DH, Hallemeier CL, Blackmon S, Yoon HH. Pembrolizumab in Combination with Neoadjuvant Chemoradiotherapy for Patients with Resectable Adenocarcinoma of the Gastroesophageal Junction. Clin Cancer Res. 2022 Jul 15; 28 (14):3021-3031
    View PubMed
  25. Davidson T, Zhang H, Dong H, Grams MP, Park SS, Yan Y. Overcoming Immunotherapy Resistance With Radiation Therapy and Dual Immune Checkpoint Blockade. Adv Radiat Oncol. 2022 Jul-Aug; 7 (4):100931 Epub 2022 Mar 01
    View PubMed
  26. Mahmoud AM, Frank I, Orme JJ, Lavoie RR, Thapa P, Costello BA, Cheville JC, Gupta S, Dong H, Lucien F. Evaluation of PD-L1 and B7-H3 expression as a predictor of response to adjuvant chemotherapy in bladder cancer. BMC Urol. 2022 Jun 24; 22 (1):90 Epub 2022 June 24
    View PubMed
  27. Davidson TM, Foster N, Lucien F, Markovic S, Dong H, Winters JL, Park SS, Orme JJ. Rescuing Cancer Immunity by Plasma Exchange in Metastatic Melanoma (ReCIPE-M1): protocol for a single-institution, open-label safety trial of plasma exchange to clear sPD-L1 for immunotherapy. BMJ Open. 2022 May 12; 12 (5):e050112
    View PubMed
  28. Friedman DJ, Kizerwetter M, Belmonte P, Rajcula M, Theodore K, Kim Lee HS, Shapiro MJ, Dong H, Shapiro VS. Cutting Edge: Enhanced Antitumor Immunity in ST8Sia6 Knockout Mice. J Immunol. 2022 Apr 15; 208 (8):1845-1850 Epub 2022 Apr 04
    View PubMed
  29. Sun L, Wang Y, Wang X, Navarro-Corcuera A, Ilyas S, Jalan-Sakrikar N, Gan C, Tu X, Shi Y, Tu K, Liu Q, Lou Z, Dong H, Sharpe AH, Shah VH, Kang N. PD-L1 promotes myofibroblastic activation of hepatic stellate cells by distinct mechanisms selective for TGF-beta receptor I versus II. Cell Rep. 2022 Feb 8; 38 (6):110349
    View PubMed
  30. Zhang W, Zhong W, Wang B, Yang J, Yang J, Yu Z, Qin Z, Shi A, Xu W, Zheng C, Schuchter LM, Karakousis GC, Mitchell TC, Amaravadi R, Herlyn M, Dong H, Gimotty PA, Daaboul G, Xu X, Guo W. ICAM-1-mediated adhesion is a prerequisite for exosome-induced T cell suppression. Dev Cell. 2022 Feb 7; 57 (3):329-343.e7 Epub 2022 Jan 31
    View PubMed
  31. Wen T, Barham W, Li Y, Zhang H, Gicobi JK, Hirdler JB, Liu X, Ham H, Peterson Martinez KE, Lucien F, Lavoie RR, Li H, Correia C, Monie DD, An Z, Harrington SM, Wu X, Guo R, Dronca RS, Mansfield AS, Yan Y, Markovic SN, Park SS, Sun J, Qin H, Liu MC, Vasmatzis G, Billadeau DD, Dong H. NKG7 Is a T-cell-Intrinsic Therapeutic Target for Improving Antitumor Cytotoxicity and Cancer Immunotherapy. Cancer Immunol Res. 2022 Feb; 10 (2):162-181 Epub 2021 Dec 15
    View PubMed
  32. Zhang H, Orme JJ, Abraha F, Stish BJ, Lowe VJ, Lucien F, Tryggestad EJ, Bold MS, Pagliaro LC, Choo CR, Brinkmann DH, Iott MJ, Davis BJ, Quevedo JF, Harmsen WS, Costello BA, Johnson GB, Nathan MA, Olivier KR, Pisansky TM, Kwon ED, Dong H, Park SS. Phase II Evaluation of Stereotactic Ablative Radiotherapy (SABR) and Immunity in (11)C-Choline-PET/CT-Identified Oligometastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2021 Dec 1; 27 (23):6376-6383 Epub 2021 Sept 30
    View PubMed
  33. Cheon IS, Li C, Son YM, Goplen NP, Wu Y, Cassmann T, Wang Z, Wei X, Tang J, Li Y, Marlow H, Hughes S, Hammel L, Cox TM, Goddery E, Ayasoufi K, Weiskopf D, Boonyaratanakornkit J, Dong H, Li H, Chakraborty R, Johnson AJ, Edell E, Taylor JJ, Kaplan MH, Sette A, Bartholmai BJ, Kern R, Vassallo R, Sun J. Immune signatures underlying post-acute COVID-19 lung sequelae. Sci Immunol. 2021 Nov 12; 6 (65):eabk1741
    View PubMed
  34. Lavoie RR, Gargollo PC, Ahmed ME, Kim Y, Baer E, Phelps DA, Charlesworth CM, Madden BJ, Wang L, Houghton PJ, Cheville J, Dong H, Granberg CF, Lucien F. Surfaceome Profiling of Rhabdomyosarcoma Reveals B7-H3 as a Mediator of Immune Evasion. Cancers (Basel). 2021 Sep 9; 13 (18) Epub 2021 Sept 09
    View PubMed
  35. Bansal A, Pandey MK, Barham W, Liu X, Harrington SM, Lucien F, Dong H, Park SS, DeGrado TR. Non-invasive immunoPET imaging of PD-L1 using anti-PD-L1-B11 in breast cancer and melanoma tumor model. Nucl Med Biol. 2021 Sep-Oct; 100-101:4-11 Epub 2021 May 29
    View PubMed
  36. Friedman DJ, Crotts SB, Shapiro MJ, Rajcula M, McCue S, Liu X, Khazaie K, Dong H, Shapiro VS. ST8Sia6 Promotes Tumor Growth in Mice by Inhibiting Immune Responses. Cancer Immunol Res. 2021 Aug; 9 (8):952-966 Epub 2021 June 01
    View PubMed
  37. He Y, Wang L, Wei T, Xiao YT, Sheng H, Su H, Hollern DP, Zhang X, Ma J, Wen S, Xie H, Yan Y, Pan Y, Hou X, Tang X, Suman VJ, Carter JM, Weinshilboum R, Wang L, Kalari KR, Weroha SJ, Bryce AH, Boughey JC, Dong H, Perou CM, Ye D, Goetz MP, Ren S, Huang H. FOXA1 overexpression suppresses interferon signaling and immune response in cancer. J Clin Invest. 2021 Jul 15; 131(14).
    View PubMed
  38. Kankeu Fonkoua LA, Chakrabarti S, Sonbol MB, Kasi PM, Starr JS, Liu AJ, Nevala WK, Maus RL, Bois MC, Pitot HC, Chandrasekharan C, Ross HJ, Wu TT, Graham RP, Villasboas JC, Weiss M, Foster NR, Markovic SN, Dong H, Yoon HH. Outcomes on anti-VEGFR-2/paclitaxel treatment after progression on immune checkpoint inhibition in patients with metastatic gastroesophageal adenocarcinoma. Int J Cancer. 2021 Jul 15; 149 (2):378-386 Epub 2021 Mar 26
    View PubMed
  39. Wang Y, Sinha S, Wellik LE, Secreto CR, Rech KL, Call TG, Parikh SA, Kenderian SS, Muchtar E, Hayman SR, Koehler AB, Van Dyke DL, Leis JF, Slager SL, Dong H, Kay NE, He R, Ding W. Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome. Blood Cancer J. 2021 May 10; 11 (5):86
    View PubMed
  40. Chen C, Li S, Xue J, Qi M, Liu X, Huang Y, Hu J, Dong H, Ling K. PD-L1 tumor-intrinsic signaling and its therapeutic implication in triple-negative breast cancer. JCI Insight. 2021 Apr 22; 6 (8)
    View PubMed
  41. Asmann YW, Parikh K, Bergsagel PL, Dong H, Adjei AA, Borad MJ, Mansfield AS. Inflation of tumor mutation burden by tumor-only sequencing in under-represented groups. NPJ Precis Oncol. 2021 Mar 19; 5 (1):22
    View PubMed
  42. Bearrick EN, Packiam V, Bhindi B, Lohse CM, Cheville JC, Mason RJ, Tollefson M, Harrington S, Dong H, Parker AS, Boorjian SA, Thompson RH, Leibovich BC. Creation of a primary tumor tissue expression biomarker-augmented prognostic model for patients with metastatic renal cell carcinoma. Urol Oncol. 2021 Feb; 39 (2):135.e1-135.e8 Epub 2020 Dec 09
    View PubMed
  43. Bhindi B, Bearrick EN, Cheville JC, Lohse CM, Mason RJ, Shah P, Harrington S, Zhang H, Dong H, Boorjian SA, Thompson RH, Leibovich BC. Bim expression in peritumoral lymphocytes is associated with survival in patients with metastatic clear cell renal cell carcinoma Kidney Cancer. 2021; 5 (3):129-35
  44. Gicobi JK, Barham W, Dong H. Immune resilience in response to cancer therapy. Cancer Immunol Immunother 2020 Nov; 69 (11):2165-2167
    View PubMed
  45. Breen WG, Leventakos K, Dong H, Merrell KW. Radiation and immunotherapy: emerging mechanisms of synergy. J Thorac Dis. 2020 Nov; 12 (11):7011-7023
    View PubMed
  46. Loeuillard E, Yang J, Buckarma E, Wang J, Liu Y, Conboy C, Pavelko KD, Li Y, O'Brien D, Wang C, Graham RP, Smoot RL, Dong H, Ilyas S. Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma. J Clin Invest. 2020 Oct 1; 130 (10):5380-5396
    View PubMed
  47. Yu J, Qin B, Moyer AM, Nowsheen S, Tu X, Dong H, Boughey JC, Goetz MP, Weinshilboum R, Lou Z, Wang L. Author Correction: Regulation of sister chromatid cohesion by nuclear PD-L1. Cell Res. 2020 Sep; 30 (9):823
    View PubMed
  48. Vera Aguilera J, Paludo J, McWilliams RR, Zhang H, Li Y, Kumar AB, Failing J, Kottschade LA, Block MS, Markovic SN, Dong H, Dronca RS, Yan Y. Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients. Melanoma Res. 2020 Aug; 30(4):364-375.
    View PubMed
  49. Orme JJ, Enninga EAL, Lucien-Matteoni F, Dale H, Burgstaler E, Harrington SM, Ball MK, Mansfield AS, Park SS, Block MS, Markovic SN, Yan Y, Dong H, Dronca RS, Winters JL. Therapeutic plasma exchange clears circulating soluble PD-L1 and PD-L1-positive extracellular vesicles. J Immunother Cancer. 2020 Aug; 8 (2)
    View PubMed
  50. Himes BT, Peterson TE, de Mooij T, Garcia LMC, Jung MY, Uhm S, Yan D, Tyson J, Jin-Lee HJ, Parney D, Abukhadra Y, Gustafson MP, Dietz AB, Johnson AJ, Dong H, Maus RL, Markovic S, Lucien F, Parney IF. The role of extracellular vesicles and PD-L1 in glioblastoma-mediated immunosuppressive monocyte induction. Neuro Oncol. 2020 Jul 7; 22 (7):967-978
    View PubMed
  51. Yu J, Qin B, Moyer AM, Nowsheen S, Tu X, Dong H, Boughey JC, Goetz MP, Weinshilboum R, Lou Z, Wang L. Regulation of sister chromatid cohesion by nuclear PD-L1. Cell Res. 2020 Jul; 30 (7):590-601 Epub 2020 Apr 29
    View PubMed
  52. Dong H. Seeking and destroying the evils from the inside-translating cancer immunity to fight COVID-19. Cancer Immunol Immunother 2020 Jun; 69 (6):911-912
    View PubMed
  53. Johnson RMG, Wen T, Dong H. Bidirectional signals of PD-L1 in T cells that fraternize with cancer cells. Nat Immunol 2020 Apr; 21 (4):365-366
    View PubMed
  54. Parikh K, Huether R, White K, Hoskinson D, Beaubier N, Dong H, Adjei AA, Mansfield AS. Tumor Mutational Burden From Tumor-Only Sequencing Compared With Germline Subtraction From Paired Tumor and Normal Specimens. JAMA Netw Open. 2020 Feb 5; 3 (2):e200202 Epub 2020 Feb 05
    View PubMed
  55. Eckel-Passow JE, Ho TH, Serie DJ, Cheville JC, Houston Thompson R, Costello BA, Dong H, Kwon ED, Leibovich BC, Parker AS. Concordance of PD-1 and PD-L1 (B7-H1) in paired primary and metastatic clear cell renal cell carcinoma. Cancer Med. 2020 Feb; 9 (3):1152-1160 Epub 2019 Dec 12
    View PubMed
  56. Li C, Zhu B, Son YM, Wang Z, Jiang L, Xiang M, Ye Z, Beckermann KE, Wu Y, Jenkins JW, Siska PJ, Vincent BG, Prakash YS, Peikert T, Edelson BT, Taneja R, Kaplan MH, Rathmell JC, Dong H, Hitosugi T, Sun J. The Transcription Factor Bhlhe40 Programs Mitochondrial Regulation of Resident CD8(+) T Cell Fitness and Functionality. Immunity. 2020 Jan 14; 52 (1):201-202
    View PubMed
  57. Orme JJ, Jazieh KA, Xie T, Harrington S, Liu X, Ball M, Madden B, Charlesworth MC, Azam TU, Lucien F, Wootla B, Li Y, Villasboas JC, Mansfield AS, Dronca RS, Dong H. ADAM10 and ADAM17 cleave PD-L1 to mediate PD-(L)1 inhibitor resistance. Oncoimmunology. 2020; 9 (1):1744980 Epub 2020 Apr 14
    View PubMed
  58. Barham W, Guo R, Park SS, Herrmann J, Dong H, Yan Y. Case Report: Simultaneous Hyperprogression and Fulminant Myocarditis in a Patient With Advanced Melanoma Following Treatment With Immune Checkpoint Inhibitor Therapy. Front Immunol. 2020; 11:561083 Epub 2021 Feb 02
    View PubMed
  59. Duma N, Abdel-Ghani A, Yadav S, Hoversten KP, Reed CT, Sitek AN, Enninga EAL, Paludo J, Aguilera JV, Leventakos K, Lou Y, Kottschade LA, Dong H, Mansfield AS, Manochakian R, Adjei AA, Dronca RS. Sex Differences in Tolerability to Anti-Programmed Cell Death Protein 1 Therapy in Patients with Metastatic Melanoma and Non-Small Cell Lung Cancer: Are We All Equal? Oncologist. 2019 Nov; 24 (11):e1148-e1155 Epub 2019 Apr 29
    View PubMed
  60. Feng D, Qin B, Pal K, Sun L, Dutta S, Dong H, Liu X, Mukhopadhyay D, Huang S, Sinicrope FA. BRAF(V600E)-induced, tumor intrinsic PD-L1 can regulate chemotherapy-induced apoptosis in human colon cancer cells and in tumor xenografts. Oncogene. 2019 Oct; 38 (41):6752-6766 Epub 2019 Aug 12
    View PubMed
  61. Li C, Zhu B, Son YM, Wang Z, Jiang L, Xiang M, Ye Z, Beckermann KE, Wu Y, Jenkins JW, Siska PJ, Vincent BG, Prakash YS, Peikert T, Edelson BT, Taneja R, Kaplan MH, Rathmell JC, Dong H, Hitosugi T, Sun J. The Transcription Factor Bhlhe40 Programs Mitochondrial Regulation of Resident CD8(+) T Cell Fitness and Functionality. Immunity. 2019 Sep 17; 51 (3):491-507.e7
    View PubMed
  62. Barham W, Gicobi JK, Yan Y, Dronca RS, Dong H. Paradox-driven adventures in the development of cancer immunology and immunotherapy. Genes Dis. 2019 Sep; 6 (3):224-231 Epub 2019 July 10
    View PubMed
  63. Failing JJ, Dudek OA, Marin Acevedo JA, Chirila RM, Dong H, Markovic SN, Dronca RS. Biomarkers of hyperprogression and pseudoprogression with immune checkpoint inhibitor therapy. Future Oncol. 2019 Aug; 15 (22):2645-2656 Epub 2019 July 12
    View PubMed
  64. Sideras K, de Man RA, Harrington SM, Polak WG, Zhou G, Schutz HM, Pedroza-Gonzalez A, Biermann K, Mancham S, Hansen BE, Bart Takkenberg R, van Vuuren AJ, Pan Q, Ijzermans JNM, Sleijfer S, Sprengers D, Dong H, Kwekkeboom J, Bruno MJ. Circulating levels of PD-L1 and Galectin-9 are associated with patient survival in surgically treated Hepatocellular Carcinoma independent of their intra-tumoral expression levels. Sci Rep. 2019 Jul 23; 9 (1):10677 Epub 2019 July 23
    View PubMed
  65. Tu X, Qin B, Zhang Y, Zhang C, Kahila M, Nowsheen S, Yin P, Yuan J, Pei H, Li H, Yu J, Song Z, Zhou Q, Zhao F, Liu J, Zhang C, Dong H, Mutter RW, Lou Z. PD-L1 (B7-H1) Competes with the RNA Exosome to Regulate the DNA Damage Response and Can Be Targeted to Sensitize to Radiation or Chemotherapy. Mol Cell. 2019 Jun 20; 74 (6):1215-1226.e4 Epub 2019 Apr 30
    View PubMed
  66. Jalali S, Price-Troska T, Bothun C, Villasboas J, Kim HJ, Yang ZZ, Novak AJ, Dong H, Ansell SM. Reverse signaling via PD-L1 supports malignant cell growth and survival in classical Hodgkin lymphoma. Blood Cancer J. 2019 Feb 19; 9 (3):22
    View PubMed
  67. Mansfield AS, Peikert T, Smadbeck JB, Udell JBM, Garcia-Rivera E, Elsbernd L, Erskine CL, Van Keulen VP, Kosari F, Murphy SJ, Ren H, Serla VV, Schaefer Klein JL, Karagouga G, Harris FR, Sosa C, Johnson SH, Nevala W, Markovic SN, Bungum AO, Edell ES, Dong H, Cheville JC, Aubry MC, Jen J, Vasmatzis G. Neoantigenic Potential of Complex Chromosomal Rearrangements in Mesothelioma. J Thorac Oncol. 2019 Feb; 14 (2):276-287 Epub 2018 Oct 10
    View PubMed
  68. Jin X, Ding D, Yan Y, Li H, Wang B, Ma L, Ye Z, Ma T, Wu Q, Rodrigues DN, Kohli M, Jimenez R, Wang L, Goodrich DW, de Bono J, Dong H, Wu H, Zhu R, Huang H. Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-kappaB Activation and PD-L1 Expression. Mol Cell. 2019 Jan 3; 73 (1):22-35.e6 Epub 2018 Dec 06
    View PubMed
  69. Evans JD, Morris LK, Zhang H, Cao S, Liu X, Mara KC, Stish BJ, Davis BJ, Mansfield AS, Dronca RS, Iott MJ, Kwon ED, Foote RL, Olivier KR, Dong H, Park SS. Prospective Immunophenotyping of CD8(+) T Cells and Associated Clinical Outcomes of Patients With Oligometastatic Prostate Cancer Treated With Metastasis-Directed SBRT. Int J Radiat Oncol Biol Phys. 2019 Jan 1; 103 (1):229-240 Epub 2018 Sept 08
    View PubMed
  70. Wu X, Li Y, Liu X, Chen C, Harrington SM, Cao S, Xie T, Pham T, Orzechowski A, Mansfield AS, Yan Y, Kwon ED, Wang L, Ling K, Dong H. Targeting B7-H1 (PD-L1) sensitizes cancer cells to chemotherapy. Heliyon. 2018 Dec; 4 (12):e01039 Epub 2018 Dec 18
    View PubMed
  71. Liang Y, Tang H, Guo J, Qiu X, Yang Z, Ren Z, Sun Z, Bian Y, Xu L, Xu H, Shen J, Han Y, Dong H, Peng H, Fu YX. Targeting IFNalpha to tumor by anti-PD-L1 creates feedforward antitumor responses to overcome checkpoint blockade resistance. Nat Commun. 2018 Nov 2; 9 (1):4586 Epub 2018 Nov 02
    View PubMed
  72. Chen G, Huang AC, Zhang W, Zhang G, Wu M, Xu W, Yu Z, Yang J, Wang B, Sun H, Xia H, Man Q, Zhong W, Antelo LF, Wu B, Xiong X, Liu X, Guan L, Li T, Liu S, Yang R, Lu Y, Dong L, McGettigan S, Somasundaram R, Radhakrishnan R, Mills G, Lu Y, Kim J, Chen YH, Dong H, Zhao Y, Karakousis GC, Mitchell TC, Schuchter LM, Herlyn M, Wherry EJ, Xu X, Guo W. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature. 2018 Aug; 560 (7718):382-386 Epub 2018 Aug 08
    View PubMed
  73. Zhang H, Jenkins SM, Lee CT, Harrington SM, Liu Z, Dong H, Zhang L. Bim is an independent prognostic marker in intrahepatic cholangiocarcinoma. Hum Pathol. 2018 Aug; 78:97-105 Epub 2018 Apr 23
    View PubMed
  74. Ye Z, Dong H, Li Y, Ma T, Huang H, Leong HS, Eckel-Passow J, Kocher JA, Liang H, Wang L. Prevalent Homozygous Deletions of Type I Interferon and Defensin Genes in Human Cancers Associate with Immunotherapy Resistance. Clin Cancer Res. 2018 Jul 15; 24 (14):3299-3308 Epub 2018 Apr 04
    View PubMed
  75. Chakrabarti S, Dong H, Paripati HR, Ross HJ, Yoon HH. First Report of Dramatic Tumor Responses with Ramucirumab and Paclitaxel After Progression on Pembrolizumab in Two Cases of Metastatic Gastroesophageal Adenocarcinoma. Oncologist. 2018 Jul; 23 (7):840-843 Epub 2018 Apr 19
    View PubMed
  76. Yan Y, Cao S, Liu X, Harrington SM, Bindeman WE, Adjei AA, Jang JS, Jen J, Li Y, Chanana P, Mansfield AS, Park SS, Markovic SN, Dronca RS, Dong H. CX3CR1 identifies PD-1 therapy-responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy. JCI Insight. 2018 Apr 19; 3 (8)
    View PubMed
  77. Enninga EAL, Harrington SM, Creedon DJ, Ruano R, Markovic SN, Dong H, Dronca RS. Immune checkpoint molecules soluble program death ligand 1 and galectin-9 are increased in pregnancy. Am J Reprod Immunol. 2018 Feb; 79(2). Epub 2017 Dec 04.
    View PubMed
  78. Tang H, Liang Y, Anders RA, Taube JM, Qiu X, Mulgaonkar A, Liu X, Harrington SM, Guo J, Xin Y, Xiong Y, Nham K, Silvers W, Hao G, Sun X, Chen M, Hannan R, Qiao J, Dong H, Peng H, Fu YX. PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression. J Clin Invest. 2018 Feb 1; 128 (2):580-588 Epub 2018 Jan 16
    View PubMed
  79. Mansfield AS, Ren H, Sutor S, Sarangi V, Nair A, Davila J, Elsbernd LR, Udell JB, Dronca RS, Park S, Markovic SN, Sun Z, Halling KC, Nevala WK, Aubry MC, Dong H, Jen J. Contraction of T cell richness in lung cancer brain metastases. Sci Rep. 2018 Feb 1; 8 (1):2171 Epub 2018 Feb 01
    View PubMed
  80. Yan Y, Kumar AB, Finnes H, Markovic SN, Park S, Dronca RS, Dong H. Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy. Front Immunol. 2018; 9:1739. Epub 2018 Jul 27.
    View PubMed
  81. Sharma V, Dong H, Kwon E, Karnes RJ. Positive Pelvic Lymph Nodes in Prostate Cancer Harbor Immune Suppressor Cells To Impair Tumor-reactive T Cells. Eur Urol Focus. 2018 Jan; 4 (1):75-79 Epub 2016 Sept 21
    View PubMed
  82. Lehrke HD, Graham RP, McWilliams RR, Lam-Himlin DM, Smyrk TC, Jenkins S, Dong H, Zhang L. Undifferentiated Pancreatic Carcinomas Display Enrichment for Frequency and Extent of PD-L1 Expression by Tumor Cells. Am J Clin Pathol. 2017 Nov 2; 148 (5):441-449
    View PubMed
  83. Zhou G, Sprengers D, Boor PPC, Doukas M, Schutz H, Mancham S, Pedroza-Gonzalez A, Polak WG, de Jonge J, Gaspersz M, Dong H, Thielemans K, Pan Q, IJzermans JNM, Bruno MJ, Kwekkeboom J. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas. Gastroenterology. 2017 Oct; 153 (4):1107-1119.e10 Epub 2017 June 23
    View PubMed
  84. Ding W, LaPlant BR, Call TG, Parikh SA, Leis JF, He R, Shanafelt TD, Sinha S, Le-Rademacher J, Feldman AL, Habermann TM, Witzig TE, Wiseman GA, Lin Y, Asmus E, Nowakowski GS, Conte MJ, Bowen DA, Aitken CN, Van Dyke DL, Greipp PT, Liu X, Wu X, Zhang H, Secreto CR, Tian S, Braggio E, Wellik LE, Micallef I, Viswanatha DS, Yan H, Chanan-Khan AA, Kay NE, Dong H, Ansell SM. Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. Blood. 2017 Jun 29; 129 (26):3419-3427 Epub 2017 Apr 19
    View PubMed
  85. Xue J, Chen C, Qi M, Huang Y, Wang L, Gao Y, Dong H, Ling K. Type Igamma phosphatidylinositol phosphate kinase regulates PD-L1 expression by activating NF-kappaB. Oncotarget. 2017 Jun 27; 8 (26):42414-42427
    View PubMed
  86. Ni X, Song Q, Cassady K, Deng R, Jin H, Zhang M, Dong H, Forman S, Martin PJ, Chen YZ, Wang J, Zeng D. PD-L1 interacts with CD80 to regulate graft-versus-leukemia activity of donor CD8+ T cells. J Clin Invest. 2017 May 01; 127: (5)1960-1977.
    View PubMed
  87. Pavelko KD, Bell MP, Harrington SM, Dong H. B7-H1 Influences the Accumulation of Virus-Specific Tissue Resident Memory T Cells in the Central Nervous System. Front Immunol. 2017; 8:1532 Epub 2017 Nov 09
    View PubMed
  88. Terra SBSP, Mansfield AS, Dong H, Peikert T, Roden AC. Temporal and spatial heterogeneity of programmed cell death 1-Ligand 1 expression in malignant mesothelioma. Oncoimmunology. 2017; 6 (11):e1356146 Epub 2017 July 27
    View PubMed
  89. Gibbons Johnson RM, Dong H. Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells. Front Immunol. 2017; 8:961 Epub 2017 Aug 10
    View PubMed
  90. Dong H, Yan Y, Dronca RS, Markovic SN. A T cell equation as a conceptual model of T cell responses for maximizing the efficacy of cancer immunotherapy. SOJ Immunol. 2017; 5 (1):1-5 Epub 2017 Feb 25
    View PubMed
  91. Dronca RS, Mansfield AS, Park SS, Dong H. BCL-2-interacting mediator of cell death (Bim) is a novel biomarker for response to anti-PD-1 therapy in patients with advanced melanoma. Immunotherapy 2016 Dec; 8 (12):1351-1353 Epub 2016 Oct 27
    View PubMed
  92. Liu X, Wu X, Cao S, Harrington SM, Yin P, Mansfield AS, Dong H. B7-H1 antibodies lose antitumor activity due to activation of p38 MAPK that leads to apoptosis of tumor-reactive CD8(+) T cells. Sci Rep. 2016 Nov 8; 6:36722 Epub 2016 Nov 08
    View PubMed
  93. Yin P, Liu X, Mansfield AS, Harrington SM, Li Y, Yan Y, Dong H. CpG-induced antitumor immunity requires IL-12 in expansion of effector cells and down-regulation of PD-1. Oncotarget. 2016 Oct 25; 7 (43):70223-70231
    View PubMed
  94. Mansfield AS, Aubry MC, Moser JC, Harrington SM, Dronca RS, Park SS, Dong H. Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer. Ann Oncol. 2016 Oct; 27 (10):1953-8 Epub 2016 Aug 08
    View PubMed
  95. Mansfield AS, Dong H. Implications of Programmed Cell Death 1 Ligand 1 Heterogeneity in the Selection of Patients With Non-Small Cell Lung Cancer to Receive Immunotherapy. Clin Pharmacol Ther. 2016 Sep; 100 (3):220-2 Epub 2016 May 03
    View PubMed
  96. Dronca RS, Liu X, Harrington SM, Chen L, Cao S, Kottschade LA, McWilliams RR, Block MS, Nevala WK, Thompson MA, Mansfield AS, Park SS, Markovic SN, Dong H. T cell Bim levels reflect responses to anti-PD-1 cancer therapy. JCI Insight. 2016 May 5; 1 (6)
    View PubMed
  97. Karyampudi L, Lamichhane P, Krempski J, Kalli KR, Behrens MD, Vargas DM, Hartmann LC, Janco JM, Dong H, Hedin KE, Dietz AB, Goode EL, Knutson KL. PD-1 Blunts the Function of Ovarian Tumor-Infiltrating Dendritic Cells by Inactivating NF-kappaB. Cancer Res. 2016 Jan 15; 76 (2):239-50 Epub 2015 Nov 13
    View PubMed
  98. Sobol I, Thompson RH, Dong H, Krco C, Kwon ED. Immunotherapy in prostate cancer. Curr Urol Rep. 2015 Jun; 16 (6):34
    View PubMed
  99. Park SS, Dong H, Liu X, Harrington SM, Krco CJ, Grams MP, Mansfield AS, Furutani KM, Olivier KR, Kwon ED. PD-1 Restrains Radiotherapy-Induced Abscopal Effect. Cancer Immunol Res. 2015 Jun; 3 (6):610-9 Epub 2015 Feb 19
    View PubMed
  100. Dave M, Hayashi Y, Gajdos GB, Smyrk TC, Svingen PA, Kvasha SM, Lorincz A, Dong H, Faubion WA Jr, Ordog T. Stem cells for murine interstitial cells of cajal suppress cellular immunity and colitis via prostaglandin E2 secretion. Gastroenterology. 2015 May; 148 (5):978-90 Epub 2015 Jan 28
    View PubMed
  101. Mansfield AS, Park SS, Dong H. Synergy of cancer immunotherapy and radiotherapy. Aging (Albany NY) 2015 Mar; 7 (3):144-5
    View PubMed
  102. Dronca RS, Dong H. Immunomodulatory antibody therapy of cancer: the closer, the better. Clin Cancer Res 2015 Mar 1; 21 (5):944-6 Epub 2014 Oct 28
    View PubMed
  103. Dronca RS, Dong H. Immunomodulatory antibody therapy of cancer: the closer, the better. Clin Cancer Res. 2015 Mar 1; 21(5):944-6. Epub 2014 Oct 28.
    View PubMed
  104. Dronca RS, Dong H. A gender factor in shaping T-cell immunity to melanoma. Front Oncol. 2015; 5:8 Epub 2015 Feb 02
    View PubMed
  105. Gibbons RM, Liu X, Harrington SM, Krco CJ, Kwon ED, Dong H. B7-H1 signaling is integrated during CD8(+) T cell priming and restrains effector differentiation. Cancer Immunol Immunother. 2014 Aug; 63(8):859-67. Epub 2014 Jun 04.
    View PubMed
  106. Mansfield AS, Roden AC, Peikert T, Sheinin YM, Harrington SM, Krco CJ, Dong H, Kwon ED. B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis. J Thorac Oncol. 2014 Jul; 9 (7):1036-1040
    View PubMed
  107. Liu X, Gibbons RM, Harrington SM, Krco CJ, Markovic SN, Kwon ED, Dong H. Endogenous tumor-reactive CD8(+) T cells are differentiated effector cells expressing high levels of CD11a and PD-1 but are unable to control tumor growth. Oncoimmunology. 2013 Jun 1; 2 (6):e23972 Epub 2013 June 06
    View PubMed
  108. Tamura H, Ishibashi M, Yamashita T, Tanosaki S, Okuyama N, Kondo A, Hyodo H, Shinya E, Takahashi H, Dong H, Tamada K, Chen L, Dan K, Ogata K. Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma. Leukemia. 2013 Feb; 27(2):464-72. Epub 2012 Jul 25.
    View PubMed
  109. Miamen AG, Dong H, Roberts LR. Immunotherapeutic approaches to hepatocellular carcinoma treatment. Liver Cancer. 2012 Nov; 1 (3-4):226-37
    View PubMed
  110. Gibbons RM, Liu X, Pulko V, Harrington SM, Krco CJ, Kwon ED, Dong H. B7-H1 limits the entry of effector CD8(+) T cells to the memory pool by upregulating Bim. Oncoimmunology. 2012 Oct 1; 1 (7):1061-1073
    View PubMed
  111. Frigola X, Inman BA, Krco CJ, Liu X, Harrington SM, Bulur PA, Dietz AB, Dong H, Kwon ED. Soluble B7-H1: differences in production between dendritic cells and T cells. Immunol Lett 2012 Feb 29; 142 (1-2):78-82 Epub 2011 Nov 25
    View PubMed
  112. Pulko V, Harris KJ, Liu X, Gibbons RM, Harrington SM, Krco CJ, Kwon ED, Dong H. B7-h1 expressed by activated CD8 T cells is essential for their survival. J Immunol. 2011 Dec 1; 187 (11):5606-14 Epub 2011 Oct 24
    View PubMed
  113. Krempski J, Karyampudi L, Behrens MD, Erskine CL, Hartmann L, Dong H, Goode EL, Kalli KR, Knutson KL. Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer. J Immunol. 2011 Jun 15; 186 (12):6905-13 Epub 2011 May 06
    View PubMed
  114. Frigola X, Inman BA, Lohse CM, Krco CJ, Cheville JC, Thompson RH, Leibovich B, Blute ML, Dong H, Kwon ED. Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma. Clin Cancer Res. 2011 Apr 1; 17 (7):1915-23 Epub 2011 Feb 25
    View PubMed
  115. Archibald DJ, Neff BA, Voss SG, Splinter PL, Driscoll CL, Link MJ, Dong H, Kwon ED. B7-H1 expression in vestibular schwannomas. Otol Neurotol. 2010 Aug; 31 (6):991-7
    View PubMed
  116. Mirza N, Duque MA, Dominguez AL, Schrum AG, Dong H, Lustgarten J. B7-H1 expression on old CD8+ T cells negatively regulates the activation of immune responses in aged animals. J Immunol. 2010 May 15; 184 (10):5466-5474 Epub 2010 Apr 07
    View PubMed
  117. Gong AY, Zhou R, Hu G, Liu J, Sosnowska D, Drescher KM, Dong H, Chen XM. Cryptosporidium parvum induces B7-H1 expression in cholangiocytes by down-regulating microRNA-513. J Infect Dis. 2010 Jan 1; 201(1):160-9.
    View PubMed
  118. Pulko V, Liu X, Krco CJ, Harris KJ, Frigola X, Kwon ED, Dong H. TLR3-stimulated dendritic cells up-regulate B7-H1 expression and influence the magnitude of CD8 T cell responses to tumor vaccination. J Immunol. 2009 Sep 15; 183 (6):3634-41 Epub 2009 Aug 26
    View PubMed
  119. Wilcox RA, Feldman AL, Wada DA, Yang ZZ, Comfere NI, Dong H, Kwon ED, Novak AJ, Markovic SN, Pittelkow MR, Witzig TE, Ansell SM. B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. Blood. 2009 Sep 3; 114 (10):2149-58 Epub 2009 July 13
    View PubMed
  120. Crispen PL, Sheinin Y, Roth TJ, Lohse CM, Kuntz SM, Frigola X, Thompson RH, Boorjian SA, Dong H, Leibovich BC, Blute ML, Kwon ED. Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma. Clin Cancer Res. 2008 Aug 15; 14 (16):5150-7 Epub 2008 Aug 11
    View PubMed
  121. Webster WS, Thompson RH, Harris KJ, Frigola X, Kuntz S, Inman BA, Dong H. Targeting molecular and cellular inhibitory mechanisms for improvement of antitumor memory responses reactivated by tumor cell vaccine. J Immunol. 2007 Sep 1; 179 (5):2860-9
    View PubMed
  122. Inman BA, Sebo TJ, Frigola X, Dong H, Bergstralh EJ, Frank I, Fradet Y, Lacombe L, Kwon ED. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer. 2007 Apr 15; 109 (8):1499-505
    View PubMed
  123. Siddiqui SA, Frigola X, Bonne-Annee S, Mercader M, Kuntz SM, Krambeck AE, Sengupta S, Dong H, Cheville JC, Lohse CM, Krco CJ, Webster WS, Leibovich BC, Blute ML, Knutson KL, Kwon ED. Tumor-infiltrating Foxp3-CD4+CD25+ T cells predict poor survival in renal cell carcinoma. Clin Cancer Res. 2007 Apr 1; 13 (7):2075-81
    View PubMed
  124. Krambeck AE, Dong H, Thompson RH, Kuntz SM, Lohse CM, Leibovich BC, Blute ML, Sebo TJ, Cheville JC, Parker AS, Kwon ED. Survivin and b7-h1 are collaborative predictors of survival and represent potential therapeutic targets for patients with renal cell carcinoma. Clin Cancer Res. 2007 Mar 15; 13 (6):1749-56
    View PubMed
  125. Thompson RH, Dong H, Lohse CM, Leibovich BC, Blute ML, Cheville JC, Kwon ED. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res. 2007 Mar 15; 13 (6):1757-61
    View PubMed
  126. Inman BA, Frigola X, Dong H, Kwon ED. Costimulation, coinhibition and cancer. Curr Cancer Drug Targets. 2007 Feb; 7 (1):15-30
    View PubMed
  127. Thompson RH, Dong H, Kwon ED. Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy. Clin Cancer Res. 2007 Jan 15; 13 (2 Pt 2):709s-715s
    View PubMed
  128. Zhang X, Dong H, Lin W, Voss S, Hinkley L, Westergren M, Tian G, Berry D, Lewellen D, Vile RG, Chen L, Farber DL, Strome SE. Human bone marrow: a reservoir for "enhanced effector memory" CD8+ T cells with potent recall function. J Immunol. 2006 Nov 15; 177(10):6730-7.
    View PubMed
  129. Krambeck AE, Thompson RH, Dong H, Lohse CM, Park ES, Kuntz SM, Leibovich BC, Blute ML, Cheville JC, Kwon ED. B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc Natl Acad Sci U S A. 2006 Jul 5; 103 (27):10391-10396 Epub 2006 June 23
    View PubMed
  130. Webster WS, Lohse CM, Thompson RH, Dong H, Frigola X, Dicks DL, Sengupta S, Frank I, Leibovich BC, Blute ML, Cheville JC, Kwon ED. Mononuclear cell infiltration in clear-cell renal cell carcinoma independently predicts patient survival. Cancer. 2006 Jul 1; 107 (1):46-53
    View PubMed
  131. Dong H, Chen X. Immunoregulatory role of B7-H1 in chronicity of inflammatory responses. Cell Mol Immunol. 2006 Jun; 3 (3):179-87
    View PubMed
  132. Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, Webster WS, Sengupta S, Frank I, Parker AS, Zincke H, Blute ML, Sebo TJ, Cheville JC, Kwon ED. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 2006 Apr 1; 66 (7):3381-5
    View PubMed
  133. Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, Chen L, Zincke H, Blute ML, Leibovich BC, Kwon ED. Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma. Cancer. 2005 Nov 15; 104 (10):2084-91
    View PubMed
  134. Thompson RH, Webster WS, Cheville JC, Lohse CM, Dong H, Leibovich BC, Kuntz SM, Sengupta S, Kwon ED, Blute ML. B7-H1 glycoprotein blockade: a novel strategy to enhance immunotherapy in patients with renal cell carcinoma. Urology. 2005 Nov; 66 (5 Suppl):10-4
    View PubMed
  135. Tamura H, Dan K, Tamada K, Nakamura K, Shioi Y, Hyodo H, Wang SD, Dong HD, Chen LP, Ogata K. Expression of functional B7-H2 and B7.2 costimulatory molecules and their prognostic implications in de novo acute myeloid leukemia. Clin Cancer Res. 2005 Aug 15; 11(16):5708-17.
    View PubMed
  136. Hirano F, Kaneko K, Tamura H, Dong H, Wang S, Ichikawa M, Rietz C, Flies DB, Lau JS, Zhu G, Tamada K, Chen L. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res. 2005 Feb 1; 65 (3):1089-96
    View PubMed
  137. Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, Krejci KG, Lobo JR, Sengupta S, Chen L, Zincke H, Blute ML, Leibovich BC, Kwon ED. Aberrant expression of costimulatory B7-H1 in clear cell renal cell carcinoma. The American Journal of Urology Review. 2005; 3(5):244-9.
  138. Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, Krejci KG, Lobo JR, Sengupta S, Chen L, Zincke H, Blute ML, Strome SE, Leibovich BC, Kwon ED. Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A. 2004 Dec 7; 101 (49):17174-9 Epub 2004 Nov 29
    View PubMed
  139. Roden AC, Moser MT, Tri SD, Mercader M, Kuntz SM, Dong H, Hurwitz AA, McKean DJ, Celis E, Leibovich BC, Allison JP, Kwon ED. Augmentation of T cell levels and responses induced by androgen deprivation. J Immunol. 2004 Nov 15; 173 (10):6098-108
    View PubMed
  140. Luo L, Chapoval AI, Flies DB, Zhu G, Hirano F, Wang S, Lau JS, Dong H, Tamada K, Flies AS, Liu Y, Chen L. B7-H3 enhances tumor immunity in vivo by costimulating rapid clonal expansion of antigen-specific CD8+ cytolytic T cells. J Immunol. 2004 Nov 1; 173 (9):5445-50
    View PubMed
  141. Dong H, Zhu G, Tamada K, Flies DB, van Deursen JM, Chen L. B7-H1 determines accumulation and deletion of intrahepatic CD8(+) T lymphocytes. Immunity. 2004 Mar; 20 (3):327-36
    View PubMed
  142. Tamura H, Ogata K, Dong H, Chen L. Immunology of B7-H1 and its roles in human diseases. Int J Hematol. 2003 Nov; 78(4):321-8.
    View PubMed
  143. Strome SE, Dong H, Tamura H, Voss SG, Flies DB, Tamada K, Salomao D, Cheville J, Hirano F, Lin W, Kasperbauer JL, Ballman KV, Chen L. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res. 2003 Oct 1; 63 (19):6501-5
    View PubMed
  144. Wang S, Bajorath J, Flies DB, Dong H, Honjo T, Chen L. Molecular modeling and functional mapping of B7-H1 and B7-DC uncouple costimulatory function from PD-1 interaction. J Exp Med. 2003 May 5; 197 (9):1083-91 Epub 2003 Apr 28
    View PubMed
  145. Curiel TJ, Wei S, Dong HD, Alvarez X, Cheng P, Mottram P, Krzysiek R, Knutson KL, Daniel B, Zimmermann MC, David O, Burow M, Gordon A, Dhurandhar N, Myers L, Berggren R, Hemminki A, Alvarez RD, Emilie D, Curiel DT, Chen LP, Zou WP. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med. 2003 May; 9(5):562-7.
    View PubMed
  146. Dong H, Chen L. B7-H1 pathway and its role in the evasion of tumor immunity. J Mol Med (Berl). 2003 May; 81 (5):281-7 Epub 2003 Apr 30
    View PubMed
  147. Trabattoni D, Saresella M, Biasin M, Boasso A, Piacentini L, Ferrante P, Dong H, Maserati R, Shearer GM, Chen L, Clerici M. B7-H1 is up-regulated in HIV infection and is a novel surrogate marker of disease progression. Blood. 2003 Apr 1; 101(7):2514-20. Epub 2002 Dec 05.
    View PubMed
  148. Dong H, Strome SE, Matteson EL, Moder KG, Flies DB, Zhu G, Tamura H, Driscoll CL, Chen L. Costimulating aberrant T cell responses by B7-H1 autoantibodies in rheumatoid arthritis. J Clin Invest. 2003 Feb; 111 (3):363-70
    View PubMed
  149. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, Lennon VA, Celis E, Chen L. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002 Aug; 8 (8):793-800 Epub 2002 June 24
    View PubMed
  150. Tamura H, Dong H, Zhu G, Sica GL, Flies DB, Tamada K, Chen L, Chen L. B7-H1 costimulation preferentially enhances CD28-independent T-helper cell function. Blood. 2001 Mar 15; 97 (6):1809-16
    View PubMed
  151. Chapoval AI, Ni J, Lau JS, Wilcox RA, Flies DB, Liu D, Dong H, Sica GL, Zhu G, Tamada K, Chen L. B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nat Immunol. 2001 Mar; 2 (3):269-74
    View PubMed
  152. Wang S, Zhu G, Chapoval AI, Dong H, Tamada K, Ni J, Chen L. Costimulation of T cells by B7-H2, a B7-like molecule that binds ICOS. Blood. 2000 Oct 15; 96 (8):2808-13
    View PubMed
  153. Shinagawa T, Dong HD, Xu M, Maekawa T, Ishii S. The sno gene, which encodes a component of the histone deacetylase complex, acts as a tumor suppressor in mice. EMBO J. 2000 May 15; 19(10):2280-91.
    View PubMed
  154. Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med. 1999 Dec; 5 (12):1365-9
    View PubMed
  155. Nomura T, Khan MM, Kaul SC, Dong HD, Wadhwa R, Colmenares C, Kohno I, Ishii S. Ski is a component of the histone deacetylase complex required for transcriptional repression by Mad and thyroid hormone receptor. Genes Dev. 1999 Feb 15; 13(4):412-23.
    View PubMed
  156. Dong H, Chen J, Chen W. Membrane molecules in induction of apoptosis of thymocytes by thymic medullar dendritic cells which express Fas ligand. Science in China. 1998; 41(2):189-94.
  157. Dong H, Xing R, Guo L, Yang C, Qian Z. Apoptosis of tumor cells in lectin-dependent lymphokine-activated killer cell-mediated cytotoxicity. J Cancer Res. 1996; 8(1):14-8.
  158. Dong H, Wang X, Shen J, Qian Z. Effect of pokeweed mitogen on the expression of HLA-DR antigen on human monocytes and leukemia cells. J Immunol. 1996; 12(4):218-21.
  159. Dong HD, Kimoto Y, Takai S, Taguchi T. Apoptosis as a mechanism of lectin-dependent monocyte-mediated cytotoxicity. Immunol Invest. 1996 Jan-Mar; 25(1-2):65-78.
    View PubMed
  160. Dong H, Xing R, Guo L. [Apoptosis of tumor cells in lectin-dependent lymphokine-activated killer cell-mediated cytotoxicity]. [Chinese]. Chung-Hua Chung Liu Tsa Chih [Chinese Journal of Oncology] 1995 Jul; 17(4):245-8.
    View PubMed
  161. Dong HD, Kimoto Y, Taguchi T. Pokeweed mitogen induces p55 interleukin-2 receptor expression on human monocytes and its effect on interleukin-2 activated monocyte cytotoxicity. Immunol Invest. 1992 Dec; 21(7):663-70.
    View PubMed
  162. Dong H, Zhao Y, Fu T, Yu L, Qian Z. Preliminary studies on the function of macrophages in different immune-deficient mice. J Immunol. 1992; 8:96-8.
  163. Dong H, Qian Z. In vitro and in vivo anti-tumor activity of cytokine-activated murine macrophages (CAM). Shanghai Journal of Immunology. 1991; 11(5):264-7.